Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The long road after breast cancer: survivorship issues and long-term treatment effects in young women.

Frontiers in oncology·2026

Same author

Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial.

Breast (Edinburgh, Scotland)·2026

Same author

Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials.

Breast (Edinburgh, Scotland)·2026

Same author

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

European journal of cancer (Oxford, England : 1990)·2026

Same author

Physical characterization of a CBCT scanner for maxillo-facial intra-surgical navigation.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2026

Same author

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

European journal of cancer (Oxford, England : 1990)·2026

Search research articles

Related Experiment Video

Updated: Jun 19, 2025

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

Published on: November 29, 2018

Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study.

Mara Caroprese¹, Manuel Conson¹, Angela Barillaro¹

¹Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Anticancer Research

|July 26, 2024

Summary

This summary is machine-generated.

Neoadjuvant systemic therapy (NAT) for breast cancer shows comparable overall survival and distant metastasis-free survival to adjuvant therapy (AD). Pathological node response is a key predictor of outcomes in NAT patients, enabling personalized treatment.

Keywords:

Breast cancer adjuvant therapy neoadjuvant systemic therapy

More Related Videos

Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis

Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis

Published on: July 29, 2017

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jun 19, 2025

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

Published on: November 29, 2018

Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis

Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis

Published on: July 29, 2017

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

Oncology
Breast Cancer Research
Clinical Therapeutics

Background:

Neoadjuvant systemic therapy (NAT) aims to improve surgical outcomes and prevent distant relapse in breast cancer.
NAT offers potential for personalized treatment by allowing therapy adjustment based on treatment response.
Evidence supporting improved outcomes with NAT compared to adjuvant therapy (AD) is still developing.

Purpose of the Study:

To evaluate the effectiveness of NAT compared to AD in breast cancer patients.
To assess overall survival (OS), loco-regional recurrence-free survival (LRRFS), and distant metastases-free survival (DMFS).
To identify prognostic factors influencing outcomes in patients treated with NAT.

Main Methods:

Retrospective analysis of 127 breast cancer patients treated with NAT and postoperative radiotherapy (2004-2021).
Comparison with a matched patient cohort treated with AD during the same period.
Outcomes analyzed included OS, LRRFS, and DMFS.

Main Results:

Five-year predicted OS: 87% (NAT) vs. 81.5% (AD) (p=0.179).
Five-year predicted LRRFS: 93.2% (NAT) vs. 100% (AD) (p=0.005).
Five-year predicted DMFS: 84.6% (NAT) vs. 82.1% (AD) (p=0.367).
In NAT group, pathological node response was a significant prognostic factor for OS (95.6% vs. 75.1%).

Conclusions:

NAT demonstrates comparable efficacy to AD in terms of DMFS and OS.
NAT provides a valuable opportunity for personalized treatment modulation, particularly in node-positive breast cancer.
Pathological node response is a critical indicator for predicting outcomes in NAT patients.